BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting (PRNewswire) - Sep 24, 2024 - "BrainStorm Cell Therapeutics Inc...today announced the acceptance of two abstracts featuring NurOwn (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting, to take place October 21 - 24, in-person in Clearwater, Florida and virtually...'Our top priority continues to be the initiation of a Phase 3b clinical trial, in order to confirm NurOwn's efficacy and conclusively demonstrate its efficacy in early stage ALS patients...As we make preparations, we anticipate multiple key milestones in the coming months that we believe will have potential to drive value.'"
Clinical data • Clinical protocol • Amyotrophic Lateral Sclerosis • CNS Disorders
|